Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation
暂无分享,去创建一个
Zhenzhen Wang | Kailin Xu | J. Crispino | Y. Wan | C. Marinaccio | Yanqing Gong | C. fu | Zengtian Sun | Hengliang Shi | Xuanxuan Shi | K. Xu | C. Fu
[1] Bian Wu. Recurrent gene mutations in chronic lymphocytic leukemia , 2017 .
[2] Delong Liu,et al. Second-generation inhibitors of Bruton tyrosine kinase , 2016, Journal of Hematology & Oncology.
[3] Kailin Xu,et al. Expression and regulation of COP1 in chronic lymphocytic leukemia cells for promotion of cell proliferation and tumorigenicity. , 2016, Oncology reports.
[4] D. Latchman,et al. Brn-3a transcription factor blocks p53-mediated activation of proapoptotic target genes Noxa and Bax in vitro and in vivo to determine cell fate. , 2015, The Journal of Biological Chemistry.
[5] S. Molica,et al. Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines , 2014, Expert review of hematology.
[6] U. Klein,et al. Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. , 2014, Blood.
[7] J. Byrd,et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.
[8] A. Yoshida,et al. COP1 targets C/EBPα for degradation and induces acute myeloid leukemia via Trib1. , 2013, Blood.
[9] S. Malek,et al. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia , 2013, Oncogene.
[10] R. Rosenquist,et al. Molecular characterization of neoplastic and normal “sister” lymphoblastoid B-cell lines from chronic lymphocytic leukemia , 2013, Leukemia & lymphoma.
[11] Chun-yu Huang,et al. High Level of COP1 Expression is Associated with Poor Prognosis in Primary Gastric Cancer , 2012, International journal of biological sciences.
[12] Xin Wang,et al. Therapeutic advancement of chronic lymphocytic leukemia , 2012, Journal of Hematology & Oncology.
[13] Jian-yong Li,et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. , 2012, Carcinogenesis.
[14] R. Wickremasinghe,et al. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies , 2011, Leukemia.
[15] S. Bogaerts,et al. Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. , 2011, The Journal of clinical investigation.
[16] P. Youinou,et al. Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia , 2010, Journal of hematology & oncology.
[17] Y. Pekarsky,et al. Molecular basis of CLL. , 2010, Seminars in cancer biology.
[18] S. Thorgeirsson,et al. Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. , 2010, Cancer research.
[19] S. Chocholska,et al. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia , 2010, Annals of Hematology.
[20] G. Simonetti,et al. A novel Rag2-/-gammac-/--xenograft model of human CLL. , 2010, Blood.
[21] R. Zhao,et al. Nuclear export regulation of COP 1 by 14-3-3 sigma in response to DNA damage , 2010 .
[22] M. Jiang,et al. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53 , 2010, Molecular Biology Reports.
[23] D. Rossi,et al. The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.
[24] Somasekar Seshagiri,et al. ATM Engages Autodegradation of the E3 Ubiquitin Ligase COP1 After DNA Damage , 2006, Science.
[25] Xing Wang Deng,et al. COP1 - from plant photomorphogenesis to mammalian tumorigenesis. , 2005, Trends in cell biology.
[26] T. Stankovic,et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.
[27] J. Pers,et al. Establishment of a novel human B-CLL-like xenograft model in nude mouse. , 2005, Leukemia research.
[28] G. Frantz,et al. COP1, the Negative Regulator of p53, Is Overexpressed in Breast and Ovarian Adenocarcinomas , 2004, Cancer Research.
[29] Chad A. Corcoran,et al. The p53 paddy wagon: COP1, Pirh2, and MDM2 are found resisting apoptosis and growth arrest , 2004, Cancer biology & therapy.
[30] Patrick Dowd,et al. The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.
[31] Haiyang Wang,et al. An initial biochemical and cell biological characterization of the mammalian homologue of a central plant developmental switch, COP1 , 2002, BMC Cell Biology.
[32] C. Schwechheimer,et al. The COP/DET/FUS proteins-regulators of eukaryotic growth and development. , 2000, Seminars in cell & developmental biology.
[33] R. Greil,et al. Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. , 2000, American journal of clinical pathology.
[34] D. Latchman,et al. p53 Suppresses the Activation of the Bcl-2 Promoter by the Brn-3a POU Family Transcription Factor* , 1999, The Journal of Biological Chemistry.
[35] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.